Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant dosesAll assessable nectin-4 positive study participants with mUC and cervical cancer ...

So, while it may necessitate staying up late, it's an excellent opportunity for skywatchers to witness the sudden brightening of T CrB — if it happens — before the star fades back into ...

Corbus Pharmaceuticals presents promising CRB-701 study results for various cancers at ASCO 2025, demonstrating safety and clinical responses. Quiver AI Summary Corbus Pharmaceuticals announced ...

The three-part Phase 1 study (NCT06265727) is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in participants with advanced solid tumors associated with high Nectin-4 expression.